# Effingham Equity – FDA 483, Jan 31, 2022

Source: https://www.keypedia.com/records/483/effingham-equity/df8e58cd-844d-4029-b529-d84c8f973e7f

> FDA 483 for Effingham Equity on January 31, 2022. Product: veterinary. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Effingham Equity
- Inspection Date: 2022-01-31
- Product Type: veterinary
- Office Name: Chicago District Office
- Summary: Effingham Equity, a medicated feed manufacturer in Effingham, IL, was cited for significant deficiencies in its hazard analysis and preventive controls for animal food safety. The inspection revealed failures to adequately control mycotoxins like aflatoxin and fumonisin in incoming ingredients, leading to contaminated livestock feed. Additionally, the firm failed to properly evaluate various hazards and lacked adequate process controls and drug identification procedures in its mixing areas.

## Related Documents

- [WARNING_LETTER - 2022-01-31](https://www.keypedia.com/records/warning_letter/effingham-equity/a6b3ecf5-447b-4123-9ec2-c7d78f1dc98a) — date: January 31, 2022

## Related Officers

- [Mark G. Peterson](https://www.keypedia.com/people/mark-g-peterson/a3442299-2fb5-4756-9155-4740d9ce0fa8)

Company: https://www.keypedia.com/companies/effingham-equity/3c903378-652a-457f-9fce-f7c859cbdab8

Office: https://www.keypedia.com/offices/chicago-district-office/a510300b-0eaf-4a33-90b5-231d95977669